Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica serovar typhimurium flagellin

Clinical and Vaccine Immunology

Volumn 20, Issue 9, 2013, Pages 1418-1425

  Leal, Monica Teixeira Andrade ^a   Camacho, Ariane Guglielmi Ariza ^a   Teixeira, Laís Helena ^a,b   Bargieri, Daniel Youssef ^a   Soares, Irene Silva ^b   Tararam, Cibele Aparecida ^a   Rodrigues, Mauricio M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; EPITOPE; FLAGELLIN; FREUND ADJUVANT; HEXAHISTIDINE TAG FLIC VK210 PLUS HEXAHISTIDINE TAG FLIC VK247 PLUS HEXAHISTIDINE TAG FLIC PLASMODIUM VIVAX LIKE FUSION PROTEIN; HEXAHISTIDINE TAG PLASMODIUM VIVAX ALL CIRCUMSPOROZOITE PROTEIN EPITOPE SALMONELLA ENTERICA SEROVAR TYPHIMURIUM FLAGELLIN FUSION PROTEIN; HEXAHISTIDINE TAG PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEIN PLASMODIUM VIVAX LIKE PROTEIN SALMONELLA ENTERICA SEROVAR TYPHIMURIUM FLAGELLIN FUSION PROTEIN; HEXAHISTIDINE TAG PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEIN VK210 SALMONELLA ENTERICA SEROVAR TYPHIMURIUM FLAGELLIN FUSION PROTEIN; HEXAHISTIDINE TAG PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEIN VK247 SALMONELLA ENTERICA SEROVAR TYPHIMURIUM FLAGELLIN FUSION PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MALARIA VACCINE; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT PROTEIN; SALMONELLA ENTERICA SEROVAR TYPHIMURIM FLAGELLIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALLELE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG DEVELOPMENT; DRUG DOSAGE FORM COMPARISON; FEMALE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMODIUM VIVAX; PRIORITY JOURNAL; RECOMBINANT GENE; SALMONELLA ENTERICA; SEROTYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; EPITOPES; FEMALE; FLAGELLIN; INJECTIONS, SUBCUTANEOUS; MALARIA VACCINES; MICE; PLASMODIUM VIVAX; POLY I-C; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM; VACCINES, SYNTHETIC;

EID: 84884695354     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00312-13     Document Type: Article

References (39)

1. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. 2010. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccin. 6:90-96.
2. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita MC, Kaboré W, Ouédraogo S, Sandrine Y, Guiguemdé RT, Ouédraogo JB, Hamel MJ, Kariuki S, Odero C, et al. 2011. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365:1863-1875.
3. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BGNO, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kaboré B, Sombié O, Guiguemdé RT, Ouédraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, et al. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284-2295.
4. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P. 2011. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anticircumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 11:102-109.
5. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, Njuguna P, Peshu N, Marsh K, Bejon P. 2013. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368:1111-1120.
6. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG, Jr, RTS,S Vaccine Evaluation Group. 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200:337-346.
7. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IRF, Baird JK, Snow RW, Hay SI. 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4:774. doi:10.1371/journal.pntd.0000774.
8. Bargieri DY, Rosa DS, Braga CJ, Carvalho BO, Costa FT, Espíndola NM, Vaz AJ, Soares IS, Ferreira LC, Rodrigues MM. 2008. New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26:6132-6142.
9. Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM. 2010. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella Typhimurium. Vaccine 28: 2818-2826.
10. Bargieri DY, Soares IS, Costa FTM, Braga CJ, Ferreira LCS, Rodrigues MM. 2011. Malaria vaccine development: are bacterial flagellin fusion proteins the bridge between mouse and humans? J. Parasitol. Res. 2011: 965369.
11. Arnot DE, Barnwell JW, Tam JP, Nussenzweig V, Nussenzweig RS, Enea V. 1985. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 230: 815-818.
12. Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, Waters AP, Prasittisuk C. 1989. Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science 245:973-976.
13. Qari SH, Shi YP, Povoa MM, Alpers MP, Deloron P, Murphy GS, Harjosuwarno S, Lal AA. 1993. Global occurrence of Plasmodium vivaxlike human malaria parasite. J. Infect. Dis. 168:1485-1489.
14. de Arruda M, Souza RC, Veiga ME, Ferreira AF, Zimmerman RH. 1998. Prevalence of Plasmodium vivax variants VK247 and P. vivax-like human malaria: a retrospective study in indigenous Indian populations of the Amazon region of Brazil. Trans. R. Soc. Trop. Med. Hyg. 92:628. doi:10.1016/S0035-9203(98)90788- X.
15. Marrelli MT, Branquinho MS, Hoffmann EH, Taipe-Lagos CB, Natal D, Kloetzel JK. 1998. Correlation between positive serology for Plasmodium vivax-like/Plasmodium simiovale malaria parasites in the human and anopheline populations in the State of Acre, Brazil. Trans. R. Soc. Trop. Med. Hyg. 92:149-151.
16. Bonilla JA, Validum L, Cummings R, Palmer CJ. 2006. Genetic diversity of Plasmodium vivax Pvcsp and Pvmsp1 in Guyana, South America. Am. J. Trop. Med. Hyg. 75:830-835.
17. Gopinath R, Wongsrichanalai C, Cordón-Rosales C, Mirabelli L, Kyle D, Kain KC. 1994. Failure to detect a Plasmodium vivax-like malaria parasite in globally collected blood samples. J. Infect. Dis. 170:1630-1633.
18. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443-451.
19. Feuillet V, Medjane S, Mondor I, Demaria O, Pagni PP, Galán JE, Flavell RA, Alexopoulou L. 2006. Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. Proc. Natl. Acad. Sci. U. S. A. 103: 12487-12492.
20. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11:115-122.
21. Camacho AG, Teixeira LH, Bargieri DY, Boscardin SB, Soares IS, Nussenzweig RS, Nussenzweig V, Rodrigues MM. 2011. TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium. Mem. Inst. Oswaldo Cruz 106(Suppl 1):167-171. http://dx.doi.org/10. 1590/S0074-0276201100090 0021.
22. Gupta RK, Siber GR. 1995. Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay. J. Immunol. Methods 181:75-81.
23. Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, Tapchaisri P, Chomcharn Y. 1982. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156:20-30.
24. Sanders CJ, Franchi L, Yarovinsky F, Uematsu S, Akira S, Nuñez G, Gewirtz AT. 2009. Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur. J. Immunol. 39:359-371.
25. Vijay-Kumar M, Carvalho FA, Aitken JD, Fifadara NH, Gewirtz AT. 2010. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur. J. Immunol. 40:3528-3534.
26. Mizel SB, Bates JT. 2010. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol. 185:5677-5682.
27. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, Breton G, Trumpfheller C, Pollak S, Shimeliovich I, Duque-Alarcon A, Pan L, Nelkenbaum A, Salazar AM, Schlesinger SJ, Steinman RM, Sékaly RP. 2011. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 208:2357-2366.
28. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I, Shaw A. 2010. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28:8268-8274.
29. Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A. 2012. Development of VAX128, a recombinant hemagglutinin (HA) influenzaflagellin fusion vaccine with improved safety and immune response. Vaccine 30:5761-5769.
30. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. 1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207:71-73.
31. Charoenvit Y, Collins WE, Jones TR, Millet P, Yuan L, Campbell GH, Beaudoin RL, Broderson JR, Hoffman SL. 1991. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 251:668-671.
32. Yadava A, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF. 2007. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect. Immun. 75:1177-1185.
33. Bell BA, Wood JF, Bansal R, Ragab H, Cargo J, III, Washington MA, Wood CL, Ware LA, Ockenhouse CF, Yadava A. 2009. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 27:1448-1453.
34. Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, Sattabongkot J, Bennett JW, Polhemus ME, Ockenhouse CF, Howard RF, Yadava A. 2011. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect. Immun. 79:3492-3500.
35. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. 2012. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. U. S. A. 109:1080-1085.
36. Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A. 2012. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 30: 3311-3319.
37. Yadava A, Nurmukhambetova S, Pichugin AV, Lumsden JM. 2012. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria. J. Infect. Dis. 205:1456-1463.
38. Corradin G, Céspedes N, Verdini A, Kajava AV, Arévalo- Herrera M, Herrera S. 2012. Malaria vaccine development using synthetic peptides as a technical platform. Adv. Immunol. 114:107-149.
39. Arévalo-Herrera M, Soto L, Perlaza BL, Céspedes N, Vera O, Lenis AM, Bonelo A, Corradin G, Herrera S. 2011. Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein. Am. J. Trop. Med. Hyg. 84(2 Suppl):35-42. doi:10.4269/ajtmh.2011.09-0507.